newsfilter
← Latest News
PR Newswire·

BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction

VANCOUVER, BC, April 25, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement with the Deaconess Research Institute ("DRI") to supply BioVaxy